Tests:Coagulation Screen: Difference between revisions
- Department
- Haematology
- Also at
- Hawera
Tests:Coagulation Screen
mNo edit summary |
m Mark as reviewed |
||
| Line 129: | Line 129: | ||
| review_ping = | | review_ping = | ||
}} | }} | ||
<!-- review-ping: 2026-10-03T02:58:39.314Z --> | |||
Latest revision as of 15:58, 3 October 2026
Overview | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Department | Haematology | ||||||||
| Test Code | CS | ||||||||
| Constituent Tests | Activated Partial Thromboplastin Time (APTT)
Fibrinogen (FIB) INR Thrombin Clotting Time (TCT) | ||||||||
| Synonyms | Clotting
Coagulation Profile Prothrombin Ratio (PR) Thrombin Clotting Time (TCT) Activated Partial Thromboplastin Time (APTT) Fibrinogen (FIB) | ||||||||
| Base Lab Availability | Monday - Sunday, testing routinely available out of hours | ||||||||
| Hawera Lab Availability | Monday - Friday, 8 am to 4 30pm | ||||||||
| Turnaround Time | 0.5 -4 hours | ||||||||
| Stability – Add test | 24 hours at room temperature (INR, PR FIB, TCT)
12 hours at room temperature (APTT) | ||||||||
Specimen Requirements | |||||||||
| Specimen | Plasma | ||||||||
| Preferred | 2.7 mL Na citrate tube Blue-Top | ||||||||
| Acceptable | |||||||||
| Unacceptable | Clotted
Over or under filled Grossly haemolysed Sample older than 24 hours - 12 hours for APTT | ||||||||
| Specimen Transportation | |||||||||
| Paediatric Requirements | 1 mL Paediatric Na citrate Blue-Top | ||||||||
Aliquot Requirements | |||||||||
| Sample | |||||||||
| Preferred Volume | |||||||||
| Minimum Volume | |||||||||
| Aliquot Transportation | |||||||||
Clinical Information | |||||||||
| Reference Intervals | Includes Prothrombin ratio, APTT, FIB and TCT.
| ||||||||
| Test Method | Mechanical clot detection performed on Stago Compact Max³ Analyser | ||||||||
| Advanced Notice | Not required | ||||||||
| Patient Preparation | Not required | ||||||||
Comments | |||||||||
| Please indicate on the request form if patient is prescribed anticoagulants. This includes, but is not limited to Warfarin, unfractionated heparin, Dabigatran, and Rivaroxaban. | |||||||||
| Owner | Craig Mabbett (Mabbett1) |
|---|---|
| Last reviewed | 3 Oct 2026 |
| Next review | 3 Oct 2027 OK |